Occult lymph node metastases in patients with carcinoma invading bladder muscle: Incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone

BJU International

Volumn 114, Issue 1, 2014, Pages 67-74

  Mertens, Laura S ^a   Meijer, Richard P ^a,c   Meinhardt, Wim ^a   Van Der Poel, Henk G ^a   Bex, Axel ^a   Kerst, J Martijn ^b   Van Der Heijden, Michiel S ^b   Bergman, Andries M ^b   Horenblas, Simon ^a   Van Rhijn, Bas W G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

bladder; cancer; chemotherapy; induction; lymph node; metastasis; neoadjuvant; urothelial

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHOTON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

BLADDER; CANCER; CHEMOTHERAPY; INDUCTION; LYMPH NODE; METASTASIS; NEOADJUVANT; UROTHELIAL;

AGED; ANTINEOPLASTIC AGENTS; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PELVIS; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84903375993     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12447     Document Type: Article

References (29)

1. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018
2. Ghoneim MA, Abdel-Latif M, el Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008; 180: 121-127
3. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG,. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176: 486-492
4. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-696
5. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675
6. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422
7. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011; 186: 1261-1268
8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866
9. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354: 533-540
10. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E,. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155: 1903-1906
11. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-205
12. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177
13. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62: 523-533
14. Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 2005; 174: 80-85
15. Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 2012; 61: 1229-1238
16. Sobin LH, Gospodarowicz MK, Wittekind CH,. TNM Classification of Malignant Tumours, 7th edn. Chichester: Wiley-Blackwell, 2009
17. Mertens LS, Meijer RP, Kerst JM, et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients? J Urol 2012; 188: 1108-1113
18. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12: 211-214
19. Meijer RP, Nunnink CJ, Wassenaar AE, et al. Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. J Urol 2012; 187: 446-450
20. Mertens LS, Meijer RP, van Werkhoven E, et al. Differences in histopathological evaluation of standard lymph node dissections results in differences in nodal count but not in survival. World J Urol 2013; 31: 1297-1302
21. Ghoneim MA, El Mekresh MM, Mokhtar AA, Gomha MA, el Baz MA, El Attar IA,. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 2000; 85: 811-816
22. Stockle M, Wellek S, Meyenburg W, et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996; 48: 868-875
23. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22: 2781-2789
24. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N,. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95: 681-695
25. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M,. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol 2005; 174: 2138-2142
26. Copp HL, Chin JL, Conaway M, Theodorescu D,. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma. Cancer 2006; 107: 60-66
27. Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O,. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006; 49: 59-70
28. Apolo AB, Riches J, Schoder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010; 28: 3973-3978
29. Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314-4320